Literature DB >> 7250143

Disposition of [4-14C]mofebutazone in the rat.

V M Bass, R I Mrongovius, K E Schulte.   

Abstract

The absorption and elimination of radioactivity after the oral or intraperitoneal administration of[4-14C]mofebutazone was studied in rats. The blood concentration of radioactivity reached a maximum after about 0.7 h, fell rapidly until about 2 h, and then declined slowly. There was sometimes a second peak between 3-6 h. Elimination of radioactivity in urine and feces was extensive and rapid. Over a 24 h period, 73% of the orally administered radioactivity was eliminated in the urine and 15% in the faeces; most of this was eliminated during the first 8 h (89% of the urine radioactivity, 56% of the faeces radioactivity). In anaesthetized rats with cannulated bile ducts, 94% of the intraperitoneally injected radioactivity was eliminated in the bile over a 6 h period. Most of the radioactivity (about 85%) eliminated in the bile and the urine was in the form of a glucuronide and only small amounts less than 10%, was in the form of mofebutazone.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7250143     DOI: 10.1007/BF03189465

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  [Toxicity and kinetics of the elimination of 4-butyl-2-phenyl-3, 5-pyrazolidinedione compared with that of the 1,2-diphenyl derivative].

Authors:  V SCARSELLI
Journal:  Farmaco Sci       Date:  1959

2.  Role of the enterohepatic circulation in the elimination of phenytoin in the rat.

Authors:  A M El-Hawari; G L Plaa
Journal:  Drug Metab Dispos       Date:  1978 Jan-Feb       Impact factor: 3.922

3.  The metabolism of phenylbutazone in the rat.

Authors:  O M Bakke; G H Draffan; D S Davies
Journal:  Xenobiotica       Date:  1974-04       Impact factor: 1.908

4.  Comparison of phenyl- and monophenylbutazone (Mobutazon), especially in respect to the incidence of side effects. A double-blind study.

Authors:  S Thune
Journal:  Acta Rheumatol Scand       Date:  1967

5.  The distribution and excretion of 14C- and 3H-labelled 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in the rat.

Authors:  H G Dean; B Donovan; P Rylett
Journal:  Arzneimittelforschung       Date:  1976

6.  Absorption of 14C-bumadizone-Ca and 14C-phenylbutazone in isolated intestinal segments in vitro and tied-off gastrointestinal sections in vivo of rats and guinea pigs.

Authors:  H Seebald; W Forth
Journal:  Arzneimittelforschung       Date:  1977

7.  Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man.

Authors:  W Dieterle; J W Faigle; H Mory; W J Richter; W Theobald
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

8.  Metabolism of phenylbutazone in man.

Authors:  W Dieterle; J W Faigle; F Früh; H Mory; W Theoblad; K O Alt; W J Richter
Journal:  Arzneimittelforschung       Date:  1976-04

9.  [Thin-layer chromatography of 1-phenyl-4n-butyl-3,5-dioxopyrazolidine (Monophenylbutazone)].

Authors:  U Salzmann
Journal:  Pharm Acta Helv       Date:  1971-12

10.  The biotransformation of phenylbutazone (Butazolidin).

Authors:  J W Faigle; W Dieterle
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

View more
  1 in total

1.  Pharmacokinetics of [4-14C] mofebutazone after oral administration in man.

Authors:  M A Kassem; K E Schulte
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.